Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4055-4063

  Mitsudomi, T ^a   Hamajima, N ^a   Ogawa, M ^a   Takahashi, T ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033765491     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
2. Staging and prognostic factors: Non-small cell lung cancer
3. p53 and lung cancer
4. Clinical significance of p53 in non-small-cell lung cancer
5. Meta-analysis in clinical trials
6. Operating characteristic of a rank correlation test for publication bias
7. p53 Nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival
8. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers
9. p53 In non-small cell lung cancer
10. Breast cancer prognostic factors: Evaluation guidelines
11. Review of survival analyses published in cancer journals
12. Meta-analysis in clinical research
13. Kirsten ras mutations in patients with colorectal cancer: The multicenter 'RASCAL' study
14. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
15. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
16. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
17. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis
18. Nuclear p53 accumulation by small-sized adenocarcinomas of the lung
19. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung
20. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus
21. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: Null mutations are associated with poor prognosis
22. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer
23. p53 Exon 5 mutations as a prognostic indicator of shortened survival in non-small cell lung cancer
24. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the 'hot spot' mutant phenotypes
25. A simple p53 functional assay for screening cell lines, blood, and tumors
26. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
27. p53 Gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features
28. p53 In non-small-cell lung cancer
29. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: A prospective study
30. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer
31. Evaluation of prognostic significance of p53 gene alterations in patients with surgically resected lung cancer
32. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer
33. Bcl-2 protein: A prognostic factor inversely correlated to p53 in non- small-cell lung cancer
34. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
35. Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer
36. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer
37. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
38. p53 Expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer
39. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung
40. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer
41. MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
42. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 Overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer
43. p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma
44. Tumor angiogenesis and biologic markers in resected stage I NSCLC
45. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer
46. The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy
47. p53 Mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer
48. The relationship of p53 immunostaining to survival in carcinoma of the lung
49. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
50. Immunohistochemical study of p53 in human lung carcinomas
51. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas
52. p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871
53. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinica course of non-small cell lung cancer
54. Immunohistochemical detection of p53 in non-small-cell lung cancer
55. Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer
56. Expression of p53 oncoprotein in non-small-cell lung cancer: A favorable prognostic factor
57. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma
58. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma
59. bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time
60. p53 Protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: Relation to prognosis
61. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis
62. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer
63. Prognostic value of p53 in non-small cell lung cancer: Relationship with proliferating cell nuclear antigen and cigarette smoking
64. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
65. p53 Status and prognosis in stage I-IIIa non-small cell lung cancer
66. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer
67. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications
68. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value
69. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers
70. Study of prognostic predictors for non-small cell lung cancer
71. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers
72. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma
73. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer
74. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer
75. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients
76. Association between p53 mutation and clinicopathological features of non-small cell lung cancer
77. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer
78. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients
79. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction
80. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection
81. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer